Source: Medicine. Unidade: ICB
Subjects: MICROBIOLOGIA, ANTICOAGULANTES, POLISSACARÍDEOS, CORONAVIRUS, DOENÇAS RESPIRATÓRIAS, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO, COVID-19, MEDICAMENTO
ABNT
BERTANHA, Matheus et al. Nebulized enriched heparin to treat no critical patients with Sars-Cov-2: triple-blind clinical trial. Medicine, v. 100, n. 51, p. 1-7, 2021Tradução . . Disponível em: https://doi.org/10.1097/MD.0000000000028288. Acesso em: 19 ago. 2024.APA
Bertanha, M., Rodrigues, L. da S., Mellucci Filho, P. L., Moroz, A., Pardini, M. I. de M. C., Sobreira, M. L., et al. (2021). Nebulized enriched heparin to treat no critical patients with Sars-Cov-2: triple-blind clinical trial. Medicine, 100( 51), 1-7. doi:10.1097/MD.0000000000028288NLM
Bertanha M, Rodrigues L da S, Mellucci Filho PL, Moroz A, Pardini MI de MC, Sobreira ML, Durigon EL, Machado RRG, Carvalho CRG. Nebulized enriched heparin to treat no critical patients with Sars-Cov-2: triple-blind clinical trial [Internet]. Medicine. 2021 ; 100( 51): 1-7.[citado 2024 ago. 19 ] Available from: https://doi.org/10.1097/MD.0000000000028288Vancouver
Bertanha M, Rodrigues L da S, Mellucci Filho PL, Moroz A, Pardini MI de MC, Sobreira ML, Durigon EL, Machado RRG, Carvalho CRG. Nebulized enriched heparin to treat no critical patients with Sars-Cov-2: triple-blind clinical trial [Internet]. Medicine. 2021 ; 100( 51): 1-7.[citado 2024 ago. 19 ] Available from: https://doi.org/10.1097/MD.0000000000028288